These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition. Baker FL; Smith KA; Mylabathula PL; Zúñiga TM; Diak DM; Batatinha H; Niemiro GM; Seckeler MD; Pedlar CR; O'Connor DP; Colombo J; Katsanis E; Simpson RJ Cancer Res Commun; 2024 May; 4(5):1253-1267. PubMed ID: 38592213 [TBL] [Abstract][Full Text] [Related]
6. Granulocyte Colony-Stimulating Factor Effectively Mobilizes TCR γδ and NK Cells Providing an Allograft Potentially Enhanced for the Graft-Versus-Leukemia Effect for Allogeneic Stem Cell Transplantation. Minculescu L; Sengelov H; Marquart HV; Ryder LP; Fischer-Nielsen A; Haastrup E Front Immunol; 2021; 12():625165. PubMed ID: 33777007 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032 [TBL] [Abstract][Full Text] [Related]
8. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation. Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H Front Immunol; 2019; 10():1997. PubMed ID: 31507601 [TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. Kabelitz D; Wesch D; Pitters E; Zöller M J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170 [TBL] [Abstract][Full Text] [Related]
10. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Zhou J; Kang N; Cui L; Ba D; He W Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706 [TBL] [Abstract][Full Text] [Related]
11. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010 [TBL] [Abstract][Full Text] [Related]
12. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120 [TBL] [Abstract][Full Text] [Related]
13. γδ T cells in cancer immunotherapy. Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972 [TBL] [Abstract][Full Text] [Related]
14. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma]. Li Z; Tang J; Sun L; Ye Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453 [TBL] [Abstract][Full Text] [Related]
16. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372 [TBL] [Abstract][Full Text] [Related]
17. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809 [TBL] [Abstract][Full Text] [Related]
18. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. Otto M; Barfield RC; Iyengar R; Gatewood J; Müller I; Holladay MS; Houston J; Leung W; Handgretinger R J Immunother; 2005; 28(1):73-8. PubMed ID: 15614047 [TBL] [Abstract][Full Text] [Related]
19. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells. Correia DV; d'Orey F; Cardoso BA; Lança T; Grosso AR; deBarros A; Martins LR; Barata JT; Silva-Santos B PLoS One; 2009 May; 4(5):e5657. PubMed ID: 19479075 [TBL] [Abstract][Full Text] [Related]
20. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain. Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]